Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): Extended follow-up of a phase 3, randomised, open-label study.
The Lancet Oncology.
Times cited: 605
Analysis of dermatologic events in vemurafenib-treated patients with melanoma.
Times cited: 129
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.
New England Journal of Medicine.
Times cited: 733